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Aim. This study assessed the 24 h circadian rhythm of intraocular pressure (IOP) using a contact lens sensor in three groups of
patients with open-angle glaucoma. Methods. This study was a monocentric, cross-sectional, nonrandomized, prospective, pilot
study. Eighty-nine patients were enrolled: 29 patients previously underwent an Ex-PRESS mini glaucoma device procedure
(Group 1), 28 patients previously underwent Hydrus microstent implantation (Group 2), and 32 patients were currently being
treated medically for primary open-angle glaucoma (Group 3). Circadian rhythm patterns were considered with five circadian
indicators: fluctuation ranges, maximum, minimum, acrophase (time of peak value), and bathyphase (time of trough value). A
two-tailed Mann–Whitney U-test was used to evaluate differences between groups. Results. All subjects exhibited a circadian
rhythm and a nocturnal pattern. The signal fluctuation range was significantly smaller in the surgical groups than in the medically
treated group (Group 1 vs. Group 3, p  0.003; Group 2 vs. Group 3, p  0.010). Subjects who underwent the Ex-PRESS
procedure (Group 1) exhibited significant differences compared with the drug therapy group (Group 3) with regard to the
minimum value (p  0.015), acrophase (p  0.009), and bathyphase (p  0.002). The other circadian indicators were not sig-
nificantly different among groups. Conclusions. Patients who underwent IOP-lowering surgery had an intrinsic nyctohemeral
rhythm. Both surgical procedures, Ex-PRESS and Hydrus, were associated with smaller signal fluctuations compared with
medical treatment.
1. Introduction
Glaucoma is the principal cause of irreversible vision loss
and the second leading cause of blindness worldwide. The
number of people aged 40–80 years with glaucoma was
estimated to be 64.3 million in 2013, and this number is
expected to increase to 76.0 million by 2020 and 111.8
million by 2040 [1]. The management of glaucoma fo-
cuses on lowering intraocular pressure (IOP), which still
remains the rational proven treatment method [2]. Current
management of glaucoma includes medical, laser, or surgical
reduction of IOP to a predetermined target.The follow-up of
glaucoma patients with single IOP measurements using
Goldmann applanation tonometry (GAT), although quick
and economically convenient, often does not adequately
reflect the untreated IOP characteristics or the quality of
treated IOP control over a 24 h period [3]. IOP is not a static
parameter but undergoes dynamic changes. Several options
for monitoring 24 h IOP are available. The most popular
method to assess an IOP curve is based on a series of single
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IOP measurements during a determined period, which re-
quires consecutive visits or hospitalization. Contact lens
sensors (CLSs) could be a better choice, particularly for
research purposes. A CLS provides 288 measurements over
24 h by sensing geometrical changes at the corneoscleral
junction every 5minutes. The main limitation of this ap-
proach is that data are given in arbitrary units (mVEq)
instead of standard tonometry pressure values (mmHg).
This device can record signal fluctuations in an outpatient
setting for up to 24 h, including during undisturbed sleep. It
provides a paradigmatic change in IOP evaluation, both
clinically and experimentally. Moreover, applying modeling
to CLS output could markedly simplify data interpretation
by providing a few circadian indicators [4].
IOP reduction remains the mainstay of glaucoma
management. The conventional stepwise algorithm involves
medical treatment, laser trabeculoplasty, and surgical
techniques. It is generally established that surgery offers
better IOP control than medical therapy, but surgery may be
associated with complications and failures. For this reason,
surgery is usually reserved for advanced or clearly pro-
gressive glaucoma. In recent years, great efforts have been
made to enhance the safety and efficacy of conventional
surgery. This is currently a rapidly evolving field, with the
development of an increasing number of innovative pro-
cedures often working on completely different bases. In the
present study, we used a CLS to characterize the 24 h cir-
cadian signal rhythm in 29 patients that had undergone Ex-
PRESS mini glaucoma device implantation, in 28 patients
that had undergone Hydrus microstent implantation, and in
32 primary open-angle glaucoma (POAG) patients that were
being treated medically. We evaluated the patterns of cir-
cadian signal fluctuation curves and five circadian in-
dicators: fluctuation range, maximum, minimum, acrophase
(time of peak value), and bathyphase (time of trough value).
2. Materials and Methods
2.1. Population. This was a monocentric, cross-sectional,
nonrandomized, prospective, pilot study performed in ac-
cordance with the tenets of the Declaration of Helsinki. The
Institutional Review Board of the Azienda Ospedaliero-
Universitaria Pisana approved the project, and all ruled-in
subjects signed the informed consent after appropriate ex-
planation of the procedure and possible consequences.
Patients were consecutively recruited from February 2016
through November 2017 in the Ophthalmology Unit, De-
partment of Surgery, at the Azienda Ospedaliero-
Universitaria of Pisa. Eighty-nine patients were enrolled
and divided into three groups based on their treatment
history: Group 1 previously underwent Ex-PRESS mini
glaucoma device implantation (29 patients, CLS applied on
the operated eye), Group 2 previously underwent Hydrus
implantation (28 patients, CLS applied on the operated eye),
and Group 3 was currently undergoing medical treatment
with two drugs (beta blockers and prostaglandin analogues
on 32 patients, CLS applied on the right eye). Surgery for
Group 1 and Group 2 had been performed at least 2 years
before by the same expert surgeon and did not require any
additional IOP-lowering drug at the time of selection.
Participants that did not sign the informed consent, did not
agree to wear the CLS, or had more than one surgical
procedure previously were excluded from the analysis. All
patients were between 18 and 80 years old and had a mean
deviation on standard automated perimetry (SAP) lower
than −4 dB.
The Ex-PRESS device (Alcon Laboratories, Fort Worth,
TX, USA) is an ab externo anterior filtering procedure that
enhances aqueous humor outflow. It is a stainless steel,
nonvalved device placed under a partial-thickness scleral
flap that diverts aqueous humor from the anterior chamber
to the subconjunctival space to create a filtration bleb. The
efficacy and safety of the device are comparable to those of
the current gold standard trabeculectomy, while reducing
both intraoperative and postoperative complications [5].
The magnitude of IOP reduction with the Ex-PRESS mini
glaucoma device is highly valuable in eyes with advanced
glaucoma where the IOP target is set as low as possible to
slow down further progression of the disease [6–9].
The Hydrus microstent (Ivantis, Irvine, CA, USA) is an
ab interno procedure that restores the natural pathway. It is a
Schlemm canal (SC) scaffold, a 8mm long nitinol device, that
is inserted with a delivery cannula into the SC. It is often
associated with cataract surgery. The idea of this device is to
dilate the SC and provide a scaffold that allows the aqueous
humor to access multiple collector channels. The device in-
creases the aqueous outflow through the trabecular mesh-
work. It is longer than other devices so it maintains a longer
length of the SC open with greater probability to involve more
collector channels. It is implanted through a clear corneal
incision under gonioscopic view [6, 10]. Preliminary results
support a favorable effectiveness and safety profile after 12 to
24months [11, 12]. Inserting the Hydrus microstent is
considered a minimally invasive glaucoma surgery (MIGS)
technique, and its intrinsic safety and efficacy may encourage
an earlier transition to surgery and reduce the latency of
topical glaucoma medication management with its associated
compliance and intolerance issues.
2.2. Measurement of 24 h IOP with CLS. All participants
underwent a screening visit including a comprehensive
ophthalmologic examination, review of medical history,
keratometry, ultrasound pachymetry, slit-lamp biomicro-
scopy, and gonioscopy. Baseline IOP was measured with
GAT, both before starting and after ending the 24 h IOP
monitoring session; each session was initiated at 9 o’clock
and completed after 24 h.
Signal monitoring was conducted with a CLS (Trig-
gerfish; Sensimed AG, Lausanne, Switzerland). Lens size was
selected among the three available base curves (8.4mm
steep, 8.7mm medium, and 9mm large). The device com-
prises a contact lens capable of recording qualitative cir-
cadian pressure-related profiles over a 24 h period under
physiologic conditions. A strain gauge embedded in a soft
silicon contact lens (sensor) captured spontaneous cir-
cumferential changes of the corneoscleral area. The data
were transmitted to a portable recorder via wireless
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telemetry. Three hundred data points were acquired every
30 seconds, repeated every 5minutes, providing a total of
288 data points at the end of 24 h. Along with the hardware
(CLS, antenna, and black box), software is provided to
graphically visualize the raw data. The device does not
measure pressure but rather measures geometrical changes:
for this reason, the data are displayed as an mVEq unit that
corresponds to mV. Many studies have validated the good
correlation of this measurement system with manometric
pressure values [4, 13, 14]. The range of fluctuations (or
amplitude, mVEq) was defined as the difference between the
maximum value (or acrophase, mVEq) and the minimum
value (or bathyphase, mVEq) over 24 h; signal fluctuation
was calculated for each patient, and then ranges in fluctu-
ations were compared between groups.
The patients had no restrictions during the 24 h recording
time as the design and purpose of this research was to detect
differences in conditions that could be representative of ev-
eryday life as much as possible. Patients pursued their routine
activities without controlling their sleep. Nonetheless, par-
ticipants were instructed to take notes in a diary ofmeaningful
facts that could affect measurement and IOP rhythm itself,
such as the time they went to bed, the time they woke up, and
the time medication was applied or consumed.
2.3. Modeling Circadian Pattern. Starting from raw data
obtained over 24 h, mathematical estimation of the signal
was made using a robust nonlinear least-squares model
based on a generalized Fourier transform (1st level):
y  a0 + a1 cos(ωx) + b1 sin ωx, (1)
where y is the observed signal (mVEq); a0, a1, and b1 are
regression coefficients; ω is the angular frequency or pul-
satance, known as the rate of change of the phase of a si-
nusoidal waveform (e.g., in oscillations and waves) or as the
rate of change of the argument of the sine function; and x is
an independent variable, which is the serial number of
recording.
We applied robust fitting to minimize the influence of
outliers using the least absolute residual (LAR) method: this
analysis minimizes the absolute difference of residuals rather
than the square difference, and therefore, extreme values
have a smaller influence on the fit. Goodness of fit was
evaluated with single parameter indicators: r2 (coefficient of
determination), r2adj (adjusted r2), and root-mean-square
error (RMSE).
A general Fourier transform was applied to data dis-
tributions of all 24 patients to classify them into pattern
groups based on the recent literature: [15–20] diurnal,
nocturnal, and unclassifiable. The diurnal pattern was de-
fined when the maximum peak occurred during the diurnal/
wakefulness period and the mean diurnal amplitude was
higher than the nocturnal amplitude. The nocturnal pattern
was defined when the maximum peak occurred during the
nocturnal/sleep period and the mean nocturnal amplitude
was higher than diurnal amplitude. The unclassifiable pat-
tern was defined when acrophase did not occur in the same
period as the maximum mean amplitude.
2.4. Statistical Analysis. This was a pilot explorative study.
Standard descriptive statistics were used both within and
between groups. Data are expressed as mean± standard
deviation (SD) where appropriate. Categorical variables are
described in terms of percentage. Outlier values are defined
according to Tukey’s range test as elements with more than
1.5 interquartile ranges above the upper quartile (75%) or
below the lower quartile (25%). The data-filling method for
outliers was performed by replacing the outlier data with the
lower threshold value for elements smaller than the lower
threshold (lower quartile) and with the upper threshold
value for elements larger than the upper threshold (upper
quartile). Statistical significance was defined at p< 0.05.
Bonferroni’s correction for multiple comparisons was ap-
plied when appropriate (p< 0.017). The Kruskal–Wallis test
was the first step to assess statistically significant differences
among the three groups, and then a two-tailed Mann–
Whitney U-test for independent samples was performed
considering two groups at a time. Analysis was performed to
compare demographic and clinical data (age (years), GAT-
IOP before and after application of CLS (mmHg), mean
deviation of SAP (dB), pattern standard deviation of SAP
(dB), and central corneal thickness (μm)), and nyctohemeral
curve parameters (ω coefficient, range of fluctuation
(mVEq), maximum (mVEq), minimum (mVEq), acrophase
(h), and bathyphase (h)). GAT-IOP before and after ap-
plication of CLS (mmHg) was investigated within groups
using the two-tailed Wilcoxon signed-rank test. All analyses
were performed using the academic analytic software
package MATLAB (MATLAB R2017a 9.2.0.538062; The
MathWorks Inc., Natick, MA, USA).
3. Results
3.1.OphthalmicData. The demographics and clinical data of
the three groups are shown in Table 1. The mean age of our
population was 73.96 years, with no difference between
groups. The patients comprised 38 men and 51 women.
Baseline IOP before CLS application and that after appli-
cation are shown in Table 1. The decrease in IOP after CLS
removal was significant only in Group 1 (p  0.031). NSAP-
mean deviation and central corneal thickness were not
significantly different at baseline among the groups. The
pattern standard deviation of SAP was greater in Group 1
than in Group 2 (p  0.01).
3.2. Circadian IOP Patterns. Circadian rhythms were suc-
cessfully recorded for a 24 h period in all patients (Figure 1).
Using equation (1), we demonstrated a circadian rhythm by
evaluating coefficient ω. If 288 measurements were obtained
in 24 h (i.e., τ  288) and pulsatance was defined as ω 2π/τ,
then ωexpected 0.0218 (Figure 2).
Table 2 shows that recorded pulsatance in Group 1 (Ex-
PRESS) was 0.021±0.003 (93.99% of ωexpected; r2 0.651–
0.996). In Group 2 (Hydrus), pulsatance was 0.025± 0.005
(exceeding 12.92% of ωexpected; r2 0.754 – 0.996). In Group 3
(medication), pulsatance was 0.021± 0.004 (94.29% of
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ωexpected; r2 0.815 – 0.995). Moreover, no statistically sig-
nificant differences were detected between groups (Table 2).
According to pattern classification, 100% of patients
belonged to the nocturnal group.
3.3. Nyctohemeral Indicators. The fluctuation range in
both surgical groups was significantly different from that in
the medically treated group (Figure 1). No significant dif-
ferences in the five nyctohemeral indicators were detected
between the surgical groups. Differences between maxi-
mum values were not significant. Patients who underwent
Ex-PRESS mini glaucoma device implantation (Group 1)
had a significantly different minimum value (p  0.015),
acrophase (p  0.009), and bathyphase (p  0.002) com-
pared with patients in drug therapy (Group 3).
All data concerning circadian indicators are shown in
Table 2 and Figure 3.
4. Discussion
We used a CLS to characterize the 24 h circadian rhythm of
IOP in patients that underwent the Ex-PRESS procedure and
Hydrus microstent implantation and POAG patients that
250
200
150
100
50
0
–50
–100
–150
–200
09:00 12:00 15:00 18:00 21:00
Time (hours)
00:00 03:00 06:00 09:00
Average IOP fluctuation
Group 1 (Ex-PRESS)
Group 2 (Hydrus)
Group 3 (drugs)
Fl
uc
tu
at
io
n 
pr
of
ile
 (m
V
Eq
)
Figure 1: Circadian signal fluctuation range in each group. A nocturnal pattern is observed for all three curves. Group 3 shows a larger signal
fluctuation range than the surgical groups (Groups 1 and 2). Group 3 peaks earlier than Group 1 in both acrophase and bathyphase.
Minimum (mVEq) is significantly deeper in Group 3 compared with Group 1. These indicators taken together implicate a smoother curve
for Group 1. Fluctuation profile’s unit (mVEq) is arbitrarily assigned by the contact lens sensor.
Table 1: Demographics and clinical data of subjects.
Ex-PRESS
(Group 1)
Hydrus
(Group 2)
Drug therapy
(Group 3)
Group 1 vs.
Group 2
(p value)
Group 1 vs.
Group 3
(p value)
Group 2 vs.
Group 3
(p value)
Age (years) 71.12± 11.42 77.75± 4.62 73.25± 4.78 0.14 0.88 0.07
Sex (M/F) 17/12 (29) 11/17 (28) 11/21 (32) — — —
Eye laterality (right/left) 17/12 (29) 9/19 (28) 13/19 (32) — — —
GAT-IOP before CLS application (mmHg) 17.62± 3.42 16.62± 3.11 17.25± 3.11 0.59 0.89 0.59
GAT-IOP after CLS removal (mmHg) 14.25± 2.55 15.65± 1.60 15.87± 3.90 0.23 0.45 0.78
CCT (μm) 474± 47.27 515.12± 20.25 528.12± 18.43 0.082 0.016 0.15
MD of SAP (dB) −14.37± 9.74 −5.00± 2.22 −6.07± 2.19 0.021 0.038 0.38
PSD of SAP (dB) 9.42± 4.61 4.21± 2.13 6.38± 3.05 0.015∗ 0.16 0.13
Data are expressed as mean± SD, except for sex and eye laterality. SD, standard deviation; p, probability value of statistical hypothesis testing; GAT-IOP,
Goldmann applanation tonometry intraocular pressure; CLS, contact lens sensor; CCT, central corneal thickness; MD, mean deviation; SAP, standard
automated perimetry; PSD, pattern standard deviation; mmHg, millimeters of mercury; dB, decibel. ∗Significant values by the Mann–Whitney U-test with
Bonferroni’s correction for multiple comparisons (p< 0.017).
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Figure 2: Continued.
Journal of Ophthalmology 5
were treated medically. Currently, the most common
method for studying IOP rhythm in glaucoma patients is
through a diurnal tension curve. Nighttime IOP monitoring
requires hospitalization or sleep laboratories, and not only it
is costly but it does not provide reliable data due to patients’
awakening during the sleep period, which potentially in-
troduces stress-related artifacts. Due to the lack of available
IOP-recording techniques that do not interfere with the
sleep cycle, IOP rhythms have been quite unexplored until
recently [21–23].
IOP is a dynamic parameter with an individual rhythm,
and potentially informative indicators, such as IOP fluctu-
ation and peak IOP, are still neglected in clinical practice.
Moreover, the effects of IOP-lowering interventions on such
measures are largely uninvestigated. Maximum IOP peak is a
case in point: it is widely accepted that the highest IOP values
occur at night, outside office hours [24, 25]. A telemetric
sensor may overcome this limitation by providing contin-
uous 24 h IOP monitoring. We used a Sensimed Triggerfish
CLS to record 288 measurements over 24 h. The main
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Figure 2: Examples of mean sine modeling of each group according to a robust nonlinear least-squares model based on a generalized
Fourier transform (Section 3). Dots indicate the mean of observed values, and the solid line indicates the modeling function. Goodness of fit
was evaluated by the sum of squares due to error (SSE), coefficient of determination (r2), adjusted coefficient of determination (adjusted r2),
and root-mean-square error (RMSE). (a) Group 1 (Ex-PRESS) coefficients: a0−10.15; a1 12.45; b1−99.1; ω 0.021; goodness of fit: SSE:
1.089e+ 05; r2: 0.921; adjusted r2: 0.920; RMSE: 19.58. (b) Group 2 (Hydrus) coefficients: a0−10.15; a1 12.45; b1−99.1; ω 0.025;
goodness of fit: SSE: 1.089e+ 05; r2: 0.921; adjusted r2: 0.920; RMSE: 19.58. (c) Group 3 (drugs) coefficients: a0 47.43; a1−93.41;
b1−99.03; ω 0.021; goodness of fit: SSE: 7.21e+ 04; r2: 0.976; adjusted r2: 0.975; RMSE: 15.93.
Table 2: Circadian indicators.
Ex-PRESS
(Group 1)
Hydrus
(Group 2)
Drug therapy
(Group 3)
Group 1 vs.
Group 2
(p value)
Group 1 vs.
Group 3
(p value)
Group 2 vs.
Group 3
(p value)
Observed circadian pattern, n/n (%) 29/29 (100) 28/28 (100) 32/32 (100) — — —
Nocturnal pattern recorded, n/n (%) 29/29 (100) 28/28 (100) 32/32 (100) — — —
Coefficient ω 0.021± 0.00 0.025± 0.01 0.021± 0.00 0.26 0.62 0.13
Fluctuation range (mVEq) 319.32± 53.26 305.75± 9.44 477.70± 92.74 0.57 0.003∗ 0.010∗
Maximum (mVEq) 221.22± 60.04 149.39± 97.49 267.97± 85.38 0.08 0.33 0.021
Minimum (mVEq) −98.11± 58.86 −156.36± 91.63 −209.72± 97.53 0.06 0.015∗ 0.033
Acrophase (h) 04 : 53± 1 : 59 04 : 01± 2 : 51 22 : 26± 4 : 58 0.98 0.009∗ 0.083
Bathyphase (h) 14 :19± 2 : 22 14 :11± 3 : 23 11 :12± 1 :18 0.57 0.002∗ 0.041
Data are expressed as mean± SD, except for observed circadian pattern and eye nocturnal pattern recorded. SD, standard deviation; p, probability value of
statistical hypothesis testing; n, number of patients; mVEq, millivolt equivalent, an arbitrary unit provided by the contact lens sensor; h, hours. ∗Significant
values by the Mann–Whitney U-test with Bonferroni’s correction for multiple comparisons (p< 0.017).
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Figure 3: Boxplot and statistics of circadian indicators. (a) Fluctuation range. (b) Maximum. (c) Minimum. (d) Acrophase (time to peak).
(e) Bathyphase (time to peak). mVEq, millivolt equivalent, an arbitrary unit provided by the contact lens sensor; h, hours; ∗statistically
significant values by the Mann–Whitney U-test with Bonferroni’s correction for multiple comparisons (p< 0.017).
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limitation of such a device is that the output is not IOP
(mmHg) itself but an equivalent of electric voltage (mVEq)
induced by conformational ocular dimensional changes at
the corneal-scleral junction that are transmitted to the re-
corder [14, 21, 22].
We considered the patterns of circadian signal curves
and five circadian indicators: fluctuation ranges, maximum,
minimum, acrophase, and bathyphase. Actually, the defi-
nition of target IOP is dampening of its fluctuations
throughout the day, as these daily variations are identified as
a significant and independent risk factor for glaucomatous
progression [3, 23, 26]. Recently, Tojo et al. [18] using the
same CLS device (Sensimed Triggerfish) reported that short-
term IOP fluctuations are associated with long-term IOP
fluctuations. They found that the long-term parameter IOP
difference (difference between maximum and minimum
IOP) and IOP peak (maximum IOP) significantly correlated
with short-term IOP fluctuations (Spearman’s r 0.326,
p  0.021, and Spearman’s r 0.433, p  0.002, respec-
tively). These results strengthen both the need for a deeper
investigation of circadian parameters in a continuous 24 h
IOP monitoring and an update of the guidelines for surgical
and medical management of glaucoma.
The main findings of the present study were that the
signal fluctuation range was significantly smaller in the
surgery groups compared to themedically treated group.We
also observed that the minimum IOP was higher in the Ex-
PRESS group than in the medically treated group, but
maximum IOP did not differ between them.
Compared with the medication group, the Hydrus
microstent was more effective only in reducing the signal
fluctuation range. All of the other circadian indicators were
not significantly different between the Hydrus microstent
and the other groups. These results are not surprising be-
cause the Hydrusmicrostent is anMIGS device, whose target
IOP is in the mid-teens, but there is a growing body of
evidence suggesting that MIGS might be a viable initial
treatment option [10, 11].
Furthermore, our results indicated that all patients had a
nyctohemeral rhythm with a nocturnal acrophase, consis-
tent with the other CLS studies [15–17, 20], and provided us
with the possibility to compare groups without any pattern
biases, particularly concerning more easily affected data:
circadian indicators. A circadian rhythm with a nocturnal
acrophase was identified in medically treated POAG in
several previous reports [16, 27–29]. Mansouri et al. [28]
reported a repeatable nocturnal acrophase in 62.9% of pa-
tients, andMansouri and Shaarawy [30] reported it in 69% of
patients. Such a difference could be explained by the larger
study population and extreme variety of IOP-lowering drugs
used, both in fixed combination and as monotherapy. Our
results were much closer to those reported by Agnifili et al.
[16], who found a nocturnal pattern in 90% of patients
medically controlled with prostaglandin analogues. Pros-
taglandin analogues uniformly decrease IOP throughout the
circadian cycle [31, 32]. Thus, in patients controlled with
such pharmacologic therapy, peaks may occur more com-
monly during the night, especially the first part of the night.
Recent findings [33] indicated that prostaglandin analogues
do not affect acrophase and amplitude compared with other
classes of ocular hypotensive medications. Accordingly, we
could consider our pharmacologically treated group as a
homogeneous sample despite the use of different IOP-
lowering medications.
In addition, we found that the surgical groups exhibited a
nocturnal pattern. Few studies have assessed a nocturnal
nyctohemeral rhythmof IOP using a CLS [15, 17, 34]. Tojo et al.
[15] examined the effects of SLTon IOP fluctuations in normal-
tension glaucoma patients. They found that SLT treatment
significantly decreased IOP and decreased IOP fluctuations
during the nocturnal periods. Aptel et al. [17] studied a pop-
ulation of POAG patients after SLT and medication washout.
They reported that SLT did not significantly change the
characteristics of the 24h pattern and that 100% of patients had
a nocturnal acrophase after the medication washout.
Regarding temporal parameters, acrophase and bathy-
phase, a difference was observed between Group 1 and
Group 3. Group 1’s acrophase peaked later in the night
compared with Group 3, as did bathyphase. An invasive
surgery procedure (Ex-PRESS) could reduce the slope of the
IOP curve. Beyond reducing the IOP fluctuation range itself,
the Ex-PRESS could change the mechanism by which IOP
fluctuated within a day by lowering the IOP slope and
without interfering with the circadian rhythm.The use of the
robust nonlinear least-squares model based on a generalized
Fourier transform allowed us to study all patients with a
highly significant coefficient of determination, without any
of the a priori assumptions used in other modeling tech-
niques [16, 17, 19, 28]. Although this could be considered an
unremarkable result, it is not useless because it reveals that
therapy, both medical and surgical, did not elicit an intrinsic
natural circadian rhythm. Nevertheless, further studies are
needed to clarify this point.
A potential limitation is the corneal effect of wearing a
CLS and the efficacy of the 24 h measurements. We also
cannot exclude the possibility that artifacts like corneal
swelling may have affected our results. Although corneal
swelling is a commonly observed phenomenon when using a
CLS, Freiberg et al. [35] showed that continuous IOP
monitoring does not seem to be affected by differences in the
corneal thickness occurring overnight when wearing a CLS.
Another weakness of our study is the absence of a conversion
table for mVEq into mmHg units. The CLS recorded the
relative signal fluctuations from the starting point. The
precise relationship between the CLS output and absolute
data given by standard tonometry remains unknown. Ac-
tually, the inability to convert to mmHg does not affect our
data. On the one hand, we could not directly compare our
results with those of previous studies, specifically older
studies, while on the other hand, new parameters that can be
relatively evaluated even with conventionally agreed on
arbitrary units are gaining more and more popularity given
their importance, both experimentally and clinically, com-
pared with absolute IOP measures themselves.
In conclusion, this study is the first to compare subjects
that underwent an Ex-PRESS procedure, patients implanted
with a Hydrus microstent, and medically treated POAG
patients using a CLS for 24 h continuous IOP monitoring.
8 Journal of Ophthalmology
Based on our results, both the Ex-PRESS and Hydrus
microstent appear to be better able to manage aqueous
humor dynamics and maybe also IOP fluctuations over a
24 h period than medical treatment.
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